Ratings Vitalhub Corp.

Equities

VHI

CA92847V5018

Market Closed - Toronto S.E. Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
6.63 ^CAD	+0.15%		+2.79%	+62.50%

May. 10	Transcript : Vitalhub Corp., Q1 2024 Earnings Call, May 10, 2024
May. 10	Vitalhub Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 42.77 times its estimated earnings per share for the ongoing year.
The company's enterprise value to sales, at 4.02 times its current sales, is high.
For the last few months, analysts have been revising downwards their earnings forecast.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
VITALHUB CORP.	+62.50%	245M		-
VEEVA SYSTEMS INC.	+5.87%	32.95B		C
PRO MEDICUS LIMITED	+18.09%	7.82B		C-
SECTRA AB	+32.81%	4.17B		B-
EVOLENT HEALTH, INC.	-27.79%	2.72B		C-
LUNIT INC.	-32.48%	1.15B		-
SIMULATIONS PLUS, INC.	+10.53%	980M		C
B-SOFT CO.,LTD.	-36.79%	873M		-
VERADIGM INC.	-28.50%	831M	-	C+
SURGICAL SCIENCE SWEDEN AB	-15.67%	688M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes